Early bird pricing has been extended! Register today! https://t.co/DSyFGlEJZx https://t.co/T0QoRCn3tK

PR3+ in Lupus Nephritis https://t.co/rLdlAQYCfT https://t.co/CzLotVPwlh

Check out this engaging video exploring the pathophysiology and management of gout flares. https://t.co/LNmXZyDec1 https://t.co/nKojprg9mU

Next generation JAK-inhibition strategies As there are many JAK-inhibitors evaluated in clinical trials currently, how do you stand out? https://t.co/Pm6cCK5ltN https://t.co/h9z3nku1gZ

UKs MHRA issued a safety alert #MTX maybe associated w/ photosensitivity. Based on Coroners death (by secondary infx) report assoc w/ photosensitivity Rxn in a MTX Rx pt. Warning is because this is not a well-known side effect https://t.co/Vbl9BYMMNC https://t.co/9SyYQMTXTl https://t.co/JNqvNieqrt

Chemokine CXCL10 a potential biomarker for ILD in systemic sclerosis (SSc)? Study of 165 SSc pts (41 w/ SSc-ILD) found higher serum CXCL10 in SSc-ILD (126 vs. 78.5 pg/ml). Hi levels incr risk of ILD 2.74-fold. Most CXCL10 from inflammed lung tissues https://t.co/Z8pIAZYaC0 https://t.co/ErRsD9Msn1

Study from British Columbia, Canada, showed between 2010 & 2020, they saw 31% more new pt rheum consults (149,902); 1st time consults for inflammatory arthritis incr 28% to 51%. While time to 1st visit decr. 35%, time to DMARD initiation was unchanged https://t.co/Et7GzxKeNe https://t.co/2as2YuIV4d

Watch: Effects of Apremilast on Cardiometabolic Effects in PsA https://t.co/aKMxEfbc4c https://t.co/wjcEjLtlaC

NEW Health Policy—Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline https://t.co/WYNcVigb7n Free to read with registration on https://t.co/28wkm59DgB https://t.co/Qbm1y76o3E

Real World Experience with PEXIVAS Low Steroid Taper Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/lXTyb93ata https://t.co/kC6J9Zuurf

What do you think of the concept of "dysuricemia" - the concept that both hyperuricemia and hypouricemia influence diseases. “The lower, the better” is incorrect; the ideal is to maintain normouricemia, or optimal SU level, to reduce the urate burden https://t.co/Vi9htWTNwr https://t.co/fsx9Oq08Ak

Reconsidering Steroids Not one of us in rheumatology hasn’t prescribed steroids, but we need to reconsider how much/how often we use them. In almost every disease state we treat, we are seeing progression towards lesser and shorter courses . https://t.co/VRlCeNXyKR https://t.co/k5Uy7IHr3h